PSMA-Targeted Radioligand Therapy for Androgen Pathway Modulation-Resistant Prostate Cancer (APMR) in the Chemotherapy-Naïve Setting: A Narrative Review and Expert Commentary
Nov 2026· Current Oncology· Vol 33, pp. 667· 0 citations· 30 references
TL;DR
This review examines the emerging evidence supporting the use of PSMA-targeted RLT in select patients with chemotherapy-naïve APMR, its potential role within current treatment pathways, and key considerations for patient selection, treatment sequencing, and the involvement of an experienced medical oncologist within a multidisciplinary team.
Abstract
The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), more recently termed androgen pathway modulation-resistant prostate cancer (APMR), continues to evolve rapidly with advances in imaging techniques and prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT). Following disease progression on androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs), treatment selection remains challenging, particularly for patients who are not planned for docetaxel chemotherapy. Although docetaxel remains an important standard treatment, its relatively low real-world uptake and the frequent use of alternative strategies with limited proven efficacy highlight an important unmet need. Recent randomized trials demonstrate that PSMA-targeted RLT has improved response rates compared to an ARPI switch in patients with APMR who are chemotherapy-naïve, with a favorable tolerability profile. However, the optimal treatment sequencing relative to docetaxel chemotherapy remains unestablished. In this review, we examine the emerging evidence supporting the use of PSMA-targeted RLT in select patients with chemotherapy-naïve APMR, its potential role within current treatment pathways, and key considerations for patient selection, treatment sequencing, and the involvement of an experienced medical oncologist within a multidisciplinary team.
Abstract 177 Lu-PSMA-617 targeted radioligand therapy (RLT) received U.S. Food and Drug Administration approval in 2022 for metastatic castration-resistant prostate cancer (mCRPC) patients progressing after androgen receptor pathway inhibitors and taxane chemotherapy. Despite its efficacy, response rates vary, promptin...
Amal Paul, Keerti Sitani, Sandip Basu· World Journal of Nuclear Med...· 0 citations
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has emerged as a major therapeutic advance in metastatic castration-resistant prostate cancer (mCRPC), The phase III VISION trial demonstrated that [177Lu]Lu-PSMA-617 significantly improves overall survival and radiographic progression-free su...
H. Noamen, A. Bekkhoucha, A. Bernard-Tessier et al.· Frontiers in Medicine· 0 citations
Prostate cancer remains a leading cause of cancer-related mortality in men worldwide. While hormone therapy is effective in the early stages of advanced disease, multimodal approaches are often required as disease progresses, including radiotherapy, hormonal agents and chemotherapy. In metastatic castration-resistant p...
M. Del Re, M. Bauckneht, R. Danesi· Drugs· 0 citations
A narrative review of phase II/III trials reporting radiographic progression-free survival (rPFS) or overall survival (OS) in mCRPC, including congress data, to June 2026, graded on a five-level evidence hierarchy to propose a hypothesis-generating four-track framework for discussion between clinicians and patients.
B. Sharaf, M. Alrwashdeh, O. El Khatib et al.· Cancers· 0 citations
Abstract Introduction Prostate cancer (PCa) is the most commonly diagnosed cancer in men worldwide. A rising proportion of men present with de novo metastatic disease, a state associated with poor survival outcomes and limited curative treatment options. Within this group, a subset of patients exhibit oligometastatic d...
S. Lichtman-Mikol, J. Lang, H. Nagar et al.· BMJ Open· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.